Zobrazeno 1 - 10
of 283
pro vyhledávání: '"Jansson Löfmark R"'
Autor:
Göpel SO; Global Patient Safety BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden. Sven.gopel@astrazeneca.com., Adingupu D; Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Wang J; College of Future Technology, Peking University, Beijing, 100871, China., Semenova E; Data Sciences and Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.; Imperial College London, School of Public Health, Department of Epidemiology and Biostatistics, London, United Kingdom., Behrendt M; Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Jansson-Löfmark R; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Ahlström C; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Jönsson-Rylander AC; Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Gopaul VS; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Esterline R; Late CVRM, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, USA., Gan LM; Ribocure Pharmaceuticals AB, Gothenburg, Sweden & SuZhou Ribo Life Science Co. Ltd., Gothenburg, Sweden.; Department of Cardiology, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden., Xiao RP; College of Future Technology, Peking University, Beijing, 100871, China.
Publikováno v:
Cardiovascular diabetology [Cardiovasc Diabetol] 2024 Nov 15; Vol. 23 (1), pp. 408. Date of Electronic Publication: 2024 Nov 15.
Autor:
Boianelli A; DMPK, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 431 83 Mölndal, Sweden., Nordell P; DMPK, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 431 83 Mölndal, Sweden., Earl J; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge CB21 6GH, UK., Naylor J; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 431 83 Mölndal, Sweden., Hornigold D; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge CB21 6GH, UK., Jansson Löfmark R; DMPK, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 431 83 Mölndal, Sweden., Sundqvist M; DMPK, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, 431 83 Mölndal, Sweden.
Publikováno v:
Pharmaceutics [Pharmaceutics] 2024 Oct 08; Vol. 16 (10). Date of Electronic Publication: 2024 Oct 08.
Autor:
Karlsson C; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Johnson LK; Department of Endocrinology, Obesity and Nutrition, Vestfold Hospital Trust, Tønsberg, Norway., Greasley PJ; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Retterstøl K; The Lipid Clinic, Oslo University Hospital, Oslo, Norway.; Department of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway., Hedberg J; Medical Evidence and Observational Research, Global Medical BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden., Hall M; Early Biometrics & Statistical Innovation, Data Science & Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Hawker N; Early Biometrics & Statistical Innovation, Data Science & Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Robertsen I; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway., Havsol J; Data Science and Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Hertel JK; Department of Endocrinology, Obesity and Nutrition, Vestfold Hospital Trust, Tønsberg, Norway., Sandbu R; Department of Surgery, Vestfold Hospital Trust, Tønsberg, Norway., Skovlund E; Department of Public Health and Nursing, Norwegian University of Science and Technology (NTNU), Trondheim, Norway., Olsen T; Department of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway., Christensen H; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway., Jansson-Löfmark R; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Andersson S; Research and Early Development, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Åsberg A; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway.; Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway., Hjelmesæth J; Department of Endocrinology, Obesity and Nutrition, Vestfold Hospital Trust, Tønsberg, Norway.; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Publikováno v:
JAMA surgery [JAMA Surg] 2024 Sep 01; Vol. 159 (9), pp. 971-980.
Autor:
Kvitne KE; Department of Pharmacy, University of Oslo, Oslo, Norway., Hjelmesæth J; Department of Endocrinology, Obesity and Nutrition, Vestfold Hospital Trust, Tønsberg, Norway.; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Hovd M; Department of Pharmacy, University of Oslo, Oslo, Norway., Sandbu R; Department of Endocrinology, Obesity and Nutrition, Vestfold Hospital Trust, Tønsberg, Norway., Johnson LK; Department of Endocrinology, Obesity and Nutrition, Vestfold Hospital Trust, Tønsberg, Norway., Andersson S; Oligonucleotide Discovery, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Karlsson C; Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Christensen H; Department of Pharmacy, University of Oslo, Oslo, Norway., Jansson-Löfmark R; DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Åsberg A; Department of Pharmacy, University of Oslo, Oslo, Norway.; Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway., Robertsen I; Department of Pharmacy, University of Oslo, Oslo, Norway.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 Sep; Vol. 116 (3), pp. 647-652. Date of Electronic Publication: 2024 May 21.
Autor:
Rigal S; TissUse GmbH, Berlin, Germany., Casas B; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Department of Biomedical Engineering, Linköping University, Linköping, Sweden., Kanebratt KP; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Wennberg Huldt C; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Magnusson LU; Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Müllers E; Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Karlsson F; Data Sciences and Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Clausen M; Translational Genomics, Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Hansson SF; Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Leonard L; Data Sciences and Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Cairns J; Data Sciences and Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Jansson Löfmark R; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Ämmälä C; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Marx U; TissUse GmbH, Berlin, Germany., Gennemark P; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Department of Biomedical Engineering, Linköping University, Linköping, Sweden., Cedersund G; Department of Biomedical Engineering, Linköping University, Linköping, Sweden.; Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden., Andersson TB; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Vilén LK; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. liisa.vilen@astrazeneca.com.; Division of Pharmaceutical Biosciences, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. liisa.vilen@astrazeneca.com.
Publikováno v:
Communications biology [Commun Biol] 2024 Jul 18; Vol. 7 (1), pp. 877. Date of Electronic Publication: 2024 Jul 18.
Autor:
Kvitne KE; Department of Pharmacy, University of Oslo, Blindern, P.O. Box 1068, 0316, Oslo, Norway. k.e.kvitne@farmasi.uio.no., Hovd M; Department of Pharmacy, University of Oslo, Blindern, P.O. Box 1068, 0316, Oslo, Norway., Johnson LK; Department of Endocrinology, Obesity and Nutrition, Vestfold Hospital Trust, Tønsberg, Norway., Wegler C; Department of Pharmacy, Uppsala University, Uppsala, Sweden.; DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Karlsson C; Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Artursson P; Department of Pharmacy, Uppsala University, Uppsala, Sweden., Andersson S; Oligonucleotide Discovery, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Sandbu R; Department of Endocrinology, Obesity and Nutrition, Vestfold Hospital Trust, Tønsberg, Norway., Hjelmesæth J; Department of Endocrinology, Obesity and Nutrition, Vestfold Hospital Trust, Tønsberg, Norway.; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Skovlund E; Department of Public Health and Nursing, Norwegian University of Science and Technology, NTNU, Trondheim, Norway., Jansson-Löfmark R; DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Christensen H; Department of Pharmacy, University of Oslo, Blindern, P.O. Box 1068, 0316, Oslo, Norway., Åsberg A; Department of Pharmacy, University of Oslo, Blindern, P.O. Box 1068, 0316, Oslo, Norway.; Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway., Robertsen I; Department of Pharmacy, University of Oslo, Blindern, P.O. Box 1068, 0316, Oslo, Norway.
Publikováno v:
Clinical pharmacokinetics [Clin Pharmacokinet] 2024 Jan; Vol. 63 (1), pp. 109-120. Date of Electronic Publication: 2023 Nov 22.
Autor:
Handin N; Department of Pharmacy, Uppsala University, SE-75123 Uppsala, Sweden., Yuan D; Department of Information Technology, Uppsala University, SE-75123 Uppsala, Sweden., Ölander M; Department of Pharmacy, Uppsala University, SE-75123 Uppsala, Sweden., Wegler C; Department of Pharmacy, Uppsala University, SE-75123 Uppsala, Sweden., Karlsson C; Late-stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-43183, Sweden.; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, SE- 41345, Sweden., Jansson-Löfmark R; DMPK, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-43153, Sweden., Hjelmesæth J; Morbid Obesity Centre, Department of Medi cine, Vestfold Hospital Trust, NO-3103 Tønsberg, Norway.; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, NO-0318 Oslo, Norway., Åsberg A; Department of Pharmacy, University of Oslo, NO-0316 Oslo, Norway.; Department of Transplanation Medicin, Oslo University Hospital-Rikshospitalet, NO-0424 Oslo, Norway., Lauschke VM; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.; University of Tübingen, Tübingen, Germany., Artursson P; Department of Pharmacy, Uppsala University, SE-75123 Uppsala, Sweden.
Publikováno v:
Computational and structural biotechnology journal [Comput Struct Biotechnol J] 2023 Sep 04; Vol. 21, pp. 4361-4369. Date of Electronic Publication: 2023 Sep 04 (Print Publication: 2023).
Autor:
Hovd M; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Blindern, PO 1068, 0316, Oslo, Norway. m.h.hovd@farmasi.uio.no., Robertsen I; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Blindern, PO 1068, 0316, Oslo, Norway., Johnson LK; The Morbid Obesity Center, Vestfold Hospital Trust, P.O. Box 2168, 3103, Tønsberg, Norway., Krogstad V; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Blindern, PO 1068, 0316, Oslo, Norway., Wegler C; Department of Pharmacy, Uppsala University, P.O. Box 580, 75123, Uppsala, Sweden.; DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 431 83, Mölndal, Sweden., Kvitne KE; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Blindern, PO 1068, 0316, Oslo, Norway., Kringen MK; Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.; Department of Health Sciences, OsloMet-Oslo Metropolitan University, Oslo, Norway., Skovlund E; Department of Public Health and Nursing, Norwegian University of Science and Technology, NTNU, P.O. Box 8905, 7491, Trondheim, Norway., Karlsson C; Late-stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Andersson S; Oligonucleotide Discovery, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Artursson P; Department of Pharmacy and Science for Life Laboratory, Uppsala University, P.O. Box 580, 75123, Uppsala, Sweden., Sandbu R; The Morbid Obesity Center, Vestfold Hospital Trust, P.O. Box 2168, 3103, Tønsberg, Norway.; Department of Surgery, Vestfold Hospital Trust, Tønsberg, Norway., Hjelmesæth J; The Morbid Obesity Center, Vestfold Hospital Trust, P.O. Box 2168, 3103, Tønsberg, Norway.; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, P.O. Box 1171, 0318, Oslo, Norway., Åsberg A; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Blindern, PO 1068, 0316, Oslo, Norway.; Department of Transplantation Medicine, Oslo University Hospital, Nydalen, P.O. Box 4950, 0424, Oslo, Norway., Jansson-Löfmark R; DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 431 83, Mölndal, Sweden., Christensen H; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Blindern, PO 1068, 0316, Oslo, Norway.
Publikováno v:
Clinical pharmacokinetics [Clin Pharmacokinet] 2023 May; Vol. 62 (5), pp. 725-735. Date of Electronic Publication: 2023 Mar 29.
Autor:
Knöchel J; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca AB R&D Gothenburg, Gothenburg, Sweden., Nilsson C; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca AB R&D Gothenburg, Gothenburg, Sweden., Carlsson B; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Wernevik L; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Hofherr A; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Gennemark P; DMPK, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Jansson-Löfmark R; DMPK, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Isaksson R; Early Biometrics and Statistical Innovation, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Rydén-Bergsten T; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Hamrén B; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca AB R&D Gothenburg, Gothenburg, Sweden., Rekić D; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca AB R&D Gothenburg, Gothenburg, Sweden.
Publikováno v:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2022 Dec; Vol. 11 (12), pp. 1569-1577. Date of Electronic Publication: 2022 Oct 01.
Autor:
Kvitne KE; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway., Åsberg A; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway.; Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway., Johnson LK; The Morbid Obesity Center, Vestfold Hospital Trust, Tønsberg, Norway., Wegler C; Department of Pharmacy, Uppsala University, Uppsala, Sweden.; DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Hertel JK; The Morbid Obesity Center, Vestfold Hospital Trust, Tønsberg, Norway., Artursson P; Department of Pharmacy and Science for Life Laboratory, Uppsala University, Uppsala, Sweden., Karlsson C; Late-stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Andersson S; Oligonucleotide Discovery, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Sandbu R; The Morbid Obesity Center, Vestfold Hospital Trust, Tønsberg, Norway.; Department of Surgery, Vestfold Hospital Trust, Tønsberg, Norway., Skovlund E; Department of Public Health and Nursing, Norwegian University of Science and Technology, NTNU, Trondheim, Norway., Christensen H; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway., Jansson-Löfmark R; DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Hjelmesaeth J; The Morbid Obesity Center, Vestfold Hospital Trust, Tønsberg, Norway.; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Robertsen I; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway.
Publikováno v:
Clinical and translational science [Clin Transl Sci] 2022 Nov; Vol. 15 (11), pp. 2685-2696. Date of Electronic Publication: 2022 Sep 08.